Response to ‘‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?’ by Scherlinger et al,Annals of the Rheumatic Diseases

当前位置： X-MOL 学术 › Ann. Rheum. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Response to ‘‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?’ by Scherlinger et al
Annals of the Rheumatic Diseases ( IF 20.3 ) Pub Date : 2019-01-23 , DOI: 10.1136/annrheumdis-2018-214952
Bente Glintborg _{1,

2} , Anne Gitte Loft _{3,

4} , Emina Omerovic ₅ , Oliver Hendricks ₆ , Asta Linauskas ₇ , Jakob Espesen ₈ , Kamilla Danebod ₂ , Dorte Vendelbo Jensen ₂ , Henrik Nordin ₉ , Emil Barner Dalgaard ₁₀ , Stavros Chrysidis ₁₁ , Salome Kristensen ₁₂ , Johnny Lillelund Raun ₁₃ , Hanne Lindegaard ₁₄ , Natalia Manilo ₁₅ , Susanne Højmark Jakobsen ₁₆ , Inger Marie Jensen Hansen ₁₆ , Dorte Dalsgaard Pedersen ₁₇ , Inge Juul Sørensen _{18,

19} , Lis Smedegaard Andersen ₂₀ , Jolanta Grydehøj ₂₁ , Frank Mehnert ₂₂ , Niels Steen Krogh ₂₃ , Merete Lund Hetland ₁₉

Affiliation

The DANBIO Registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark
Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark.
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen University Hospital, Glostrup, Denmark.
Kong Christian X's Gigthospital, Gråsten, Denmark.
Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark.
Department of Rheumatology, Vejle Hospital, Vejle, Denmark.
Department of Rheumatology, Zealand University Hospital, Køge, Denmark.
Department of Rheumatology, Silkeborg Hospital, Silkeborg, Denmark.
Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark.
Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
Department of Rheumatology, Sygehus Lillebælt, Kolding, Denmark.
Department of Rheumatology, Odense University Hospital, Odense, Denmark.
Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark.
Department of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark.
Department of Rheumatology, Viborg Hospital, Viborg, Denmark.
The DANBIO Registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Internal Medicine, Rønne Hospital, Rønne, Denmark.
Department of Rheumatology, Holstebro Hospital, Holstebro, Denmark.
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
ZiteLab, Copenhagen, Denmark.

Thank you for the interest1 in our recent publication, in which we explored treatment outcomes following a Danish mandatory switch from originator to biosimilar etanercept (SB4, 50 mg) in routine care.2 We showed that of the 2061 patients who were receiving originator etanercept and thus were eligible for the switch, as many as four of five (79%) switched to the biosimilar, despite the continued availability of the originator drug (as 25 mg pen or 50 mg powder solution). Among the patients who switched, we observed high retention rates of the biosimilar. The 6-month …

中文翻译：

对“转换还是不转换”的回应：生物仿制药难题中的缺失部分？由 Scherlinger 等人撰写

感谢您对我们最近出版物的关注 1，其中我们探讨了丹麦在常规护理中强制从原研药改为生物仿制药依那西普（SB4，50 毫克）后的治疗结果。2 我们展示了在接受原研药依那西普治疗的 2061 名患者中，因此，尽管原始药物（25 毫克笔或 50 毫克粉末溶液）持续可用，但仍有多达五分之四 (79%) 转换为生物仿制药。在转换的患者中，我们观察到生物仿制药的高保留率。为期 6 个月的…

更新日期：2019-01-23

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11